Pulmonary embolism, coagulation
| (19 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
{{pnc}} | {{pnc}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | {{ | + | {{ft|D}} |
| − | + | Since there are many organ manifestations of Hypercoagulation, subcategorization and transcategorization was applied. | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | *'''[[Venous thrombosis]]''' | |
| − | + | *'''[[Pulmonary embolism]]''' | |
| − | + | *'''[[Cerebral embolism]]''' | |
| − | + | *'''[[Myocardial infarction]]''' | |
| − | + | *'''[[Arterial embolism]]''' | |
| − | + | *'''[[Microembolism]]''' | |
| − | + | *'''[[Hypercoagulation]]''' | |
| − | + | *'''[[Antiphospholipid antibodies]]''' | |
| − | + | *'''[[Disseminated intravascular coagulation]]''' | |
| − | + | *'''[[Bleeding]]''' | |
| − | + | *'''[[Labwork of Thrombembolism]]''' | |
| − | + | *'''[[Prophylaxis of Thrombembolism]]''' | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | The unifying concept behind is '''[[Dysendotheliopathies]]''' with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis. | |
| − | + | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ---- | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | {{tp|p= | + | *'''papers on various thromboembolic manifestations''' |
| − | + | {{tp|p=32281926|t=2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) |pdf=|usr=}} | |
| − | + | {{tp|p=32347323|t=ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation |pdf=|usr=}} | |
| − | {{tp|p= | + | {{tp|p=32360371|t=ä. Thromboembolic events in patients with SARS-CoV-2 |pdf=|usr=}} |
| − | + | {{tp|p=C7146714|t=ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | |
| − | {{tp|p= | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | {{tp|p= | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32324101|t=2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands |pdf=|usr=}} | {{tp|p=32324101|t=2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32133825|t=2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32133825|t=2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19 |pdf=|usr=}} | ||
| − | {{tp|p= | + | {{tp|p=32402423|t=2020. Ten key points that vascular doctors learned very quickly about COVID-19 |pdf=|usr=}} |
| − | {{tp|p= | + | {{tp|p=32381264|t=2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis |pdf=|usr=}} |
| − | {{tp|p= | + | {{tp|p=32388068|t=2020. Thrombotic complications in critically ill patients with COVID 19 |pdf=|usr=}} |
| − | {{tp|p= | + | {{tp|p=32291094|t=2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} |
| − | {{tp|p= | + | {{tp|p=32374544|t=2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives |pdf=|usr=}} |
| + | *[https://townhall.com/tipsheet/leahbarkoukis/2020/05/05/doctors-are-noticing-a-dangerous-phenomenon-even-after-wuhan-coronavirus-symptoms-are-gone-n2568192 thrombotic late reactions] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ---- | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | {{tp|p= | + | *'''papers on Hypoxemia''' |
| + | {{tp|p=32359410|t=ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT |pdf=|usr=}} | ||
{{tp|p=C7177114|t=2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes |pdf=|usr=}} | {{tp|p=C7177114|t=2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes |pdf=|usr=}} | ||
{{tp|p=32376101|t=2020. Association Between Hypoxemia and Mortality in Patients With COVID-19 |pdf=|usr=}} | {{tp|p=32376101|t=2020. Association Between Hypoxemia and Mortality in Patients With COVID-19 |pdf=|usr=}} | ||
| − | {{tp|p= | + | |
| − | {{tp|p= | + | |
| − | {{tp|p= | + | ---- |
| − | {{tp|p= | + | |
| − | {{tp|p= | + | *'''others''' |
| − | {{ttp|p= | + | {{tp|p=32462990|t=2020. COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.|pdf=|usr=007}} |
| − | {{tp|p= | + | {{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} |
| − | {{tp|p= | + | {{tp|p=32501145|t=2020. Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).|pdf=|usr=007}} |
| − | {{tp|p= | + | {{tp|p=32459857|t=2020. D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue?|pdf=|usr=007}} |
| + | {{tp|p=32314950|t=2020. Society for Vascular Medicine (SVM) Leaders Respond to the COVID-19 Crisis.|pdf=|usr=007}} | ||
| + | {{tp|p=32447301|t=2020. Coexistent COVID-19 pneumonia and pulmonary embolism: challenges in identifying dual pathology.|pdf=|usr=007}} | ||
| + | {{tp|p=32455440|t=2020. Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.|pdf=|usr=007}} | ||
| + | {{tp|p=32396963|t=2020. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?|pdf=|usr=007}} | ||
| + | {{tp|p=32512587|t=2020. Bleeding and Bleeding Risk in COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32463186|t=2020. Lungeembolisme ved covid-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32425013|t=2020. COVID-19 and coagulative axis: review of emerging aspects in a novel disease.|pdf=|usr=007}} | ||
| + | {{tp|p=32469410|t=2020. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}} | ||
| + | {{tp|p=32392741|t=2020. Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.|pdf=|usr=007}} | ||
| + | {{tp|p=32447934|t=2020. [Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia].|pdf=|usr=007}} | ||
| + | {{tp|p=32395964|t=2020. Do's-and-don'ts bij COVID-19-coagulopathie.|pdf=|usr=007}} | ||
| + | {{tp|p=32454268|t=2020. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.|pdf=|usr=007}} | ||
| + | {{tp|p=32507399|t=2020. Tromboembolismo pulmonar y COVID-19: un cambio de paradigma.|pdf=|usr=007}} | ||
| + | {{tp|p=32380898|t=2020. The "venous perspective" in Lombardia (Italy) during the first weeks of the COVID-19 epidemic.|pdf=|usr=007}} | ||
| + | {{tp|p=32490886|t=2020. Is there a rationale for heparin use among severe COVID-19 patients?|pdf=|usr=007}} | ||
| + | {{tp|p=32453702|t=2020. Procoagulatio, hypercoagulatio es fibrinolysis "shut down" kimutatasa ClotPro(R) viszkoelasztikus tesztek segitsegevel COVID-19-betegekben.|pdf=|usr=007}} | ||
| + | {{tp|p=32427809|t=2020. Inflammatory and Coagulative Considerations for the Management of Orthopaedic Trauma Patients with COVID-19: A Review of the Current Evidence and Our Surgical Experience.|pdf=|usr=007}} | ||
| + | {{tp|p=32426897|t=2020. Heparin - an old drug with multiple potential targets in Covid-19 therapy.|pdf=|usr=007}} | ||
| + | {{tp|p=32415902|t=2020. Ibuprofen and thromboembolism in SARS-COV2.|pdf=|usr=007}} | ||
| + | {{tp|p=32506364|t=2020. Hyperacute multi-organ thromboembolic storm in COVID-19: a case report.|pdf=|usr=007}} | ||
| + | {{tp|p=32504449|t=2020. Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32464707|t=2020. Macrothrombosis and stroke in patients with mild Covid-19 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32470213|t=2020. All those D-dimers in COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32470207|t=2020. Frequency of lupus anticoagulant in Covid-19 patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32470198|t=2020. Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.|pdf=|usr=007}} | ||
| + | {{tp|p=32470154|t=2020. Reply to 'Ibuprofen and thromboembolism in SARS-COV2'.|pdf=|usr=007}} | ||
| + | {{tp|p=32470156|t=2020. The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome.|pdf=|usr=007}} | ||
| + | {{tp|p=32393875|t=2020. Coronavirus blood-clot mystery intensifies.|pdf=|usr=007}} | ||
| + | {{tp|p=32497287|t=2020. Anticardiolipin antibodies and COVID-19-A case report from America.|pdf=|usr=007}} | ||
| + | {{tp|p=32495985|t=2020. The association between D-dimers in COVID-19 patients and mortality remains beset of uncertainties.|pdf=|usr=007}} | ||
| + | {{tp|p=32409435|t=2020. Coagulopathy in COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32505779|t=2020. Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?|pdf=|usr=007}} | ||
| + | {{tp|p=32512349|t=2020. Clinically significant anticardiolipin antibodies associated with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32468942|t=2020. A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32464676|t=2020. Haemostasis in Times of COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32498097|t=2020. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.|pdf=|usr=007}} | ||
| + | {{tp|p=32476551|t=2020. Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?|pdf=|usr=007}} | ||
| + | {{tp|p=32429774|t=2020. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system.|pdf=|usr=007}} | ||
| + | {{tp|p=32508034|t=2020. Predicted value of coagulation function for prognosis and admission time to negative RT-PCR detection in non-critical COVID-19 patients.|pdf=|usr=007}} | ||
| + | {{ttp|p=32508062|t=2020. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.|pdf=|usr=007}} | ||
| + | {{tp|p=32432563|t=2020. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation.|pdf=|usr=007}} | ||
| + | {{tp|p=32421381|t=2020. Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome.|pdf=|usr=007}} | ||
| + | {{tp|p=32412320|t=2020. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan.|pdf=|usr=007}} | ||
| + | {{tp|p=32508261|t=2020. Hypoalbuminemia, Coagulopathy and Vascular Disease in Covid-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32463538|t=2020. Excess out-of-hospital deaths during COVID-19 outbreak: evidence of pulmonary embolism as a main determinant.|pdf=|usr=007}} | ||
| + | {{tp|p=32406381|t=2020. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.|pdf=|usr=007}} | ||
| + | {{tp|p=32423903|t=2020. Thrombotic risk in COVID-19: a case series and case-control study.|pdf=|usr=007}} | ||
| + | {{tp|p=32491074|t=2020. COVID-19 e Estado de Hipercoagulabilidade: Uma Nova Perspectiva Terapeutica.|pdf=|usr=007}} | ||
| + | {{tp|p=32396903|t=2020. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?|pdf=|usr=007}} | ||
| + | {{tp|p=32500589|t=2020. Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D - Dimer: COVID 19 and Superficial thrombophlebitis.|pdf=|usr=007}} | ||
| + | {{ttp|p=32459672|t=2020. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.|pdf=|usr=007}} | ||
| + | {{tp|p=32503799|t=2020. Abrupt deterioration and pulmonary embolism in COVID-19: a case report.|pdf=|usr=007}} | ||
| + | {{tp|p=32452757|t=2020. Vascular injury and COVID-19-related mortality: What lies below the tip of the iceberg?|pdf=|usr=007}} | ||
| + | {{tp|p=32512408|t=2020. The choice of intravenous thrombolysis for Acute Ischemic Stroke under COVID-19 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32453688|t=2020. COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.|pdf=|usr=007}} | ||
| + | {{tp|p=32438458|t=2020. Molecular mechanisms for thrombosis risk in Black people: a role in excess mortality from COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32425273|t=2020. Pulmonary embolism and Sars-Cov-2 infection: A new indication for surgical pulmonary endarterectomy?|pdf=|usr=008}} | ||
| + | {{tp|p=32420615|t=2020. Dynamic relationship between D-dimer and COVID-19 severity.|pdf=|usr=007}} | ||
| + | {{tp|p=32510975|t=2020. Thromboprophylaxis in COVID-19: Anti-FXa - The Missing Factor?|pdf=|usr=007}} | ||
| + | {{tp|p=32383969|t=2020. Segmental Pulmonary Vascular Changes in COVID-19 Pneumonia.|pdf=|usr=007}} | ||
| + | {{tp|p=32478611|t=2020. Reply to "Segmental Pulmonary Vascular Changes in COVID-19 Pneumonia".|pdf=|usr=007}} | ||
| + | {{tp|p=32506683|t=2020. D-dimer triage for COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32484901|t=2020. Re The source of elevated plasma D-dimer levels in COVID-19 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32497248|t=2020. Pulmonary Artery Thrombectomy - A Life Saving Treatment in a Patient with Presumed COVID-19 complicated by a massive Pulmonary Embolus.|pdf=|usr=007}} | ||
| + | {{tp|p=32484907|t=2020. Prevalence of Venous Thromboembolism in Critically Ill Patients with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32420614|t=2020. First COVID-19 maternal mortality in the UK associated with thrombotic complications.|pdf=|usr=007}} | ||
| + | {{tp|p=32439704|t=2020. Covid-19 and thrombosis: what do we know about the risks and treatment?|pdf=|usr=007}} | ||
| + | {{tp|p=32462179|t=2020. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.|pdf=|usr=007}} | ||
| + | {{tp|p=32492712|t=2020. COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32425236|t=2020. Acute Pulmonary Embolism: An unseen villain in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32532932|t=2020. Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?|pdf=|usr=008}} | ||
| + | {{tp|p=32532939|t=2020. The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection|pdf=|usr=008}} | ||
| + | {{tp|p=32532948|t=2020. Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.|pdf=|usr=008}} | ||
| + | {{tp|p=32497796|t=2020. Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.|pdf=|usr=008}} | ||
| + | {{tp|p=32471650|t=2020. Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32435822|t=2020. Incidence of pulmonary embolism in patients with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32435823|t=2020. Prothrombotic phenotype in COVID-19 severe patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32405288|t=2020. Acute upper limb ischemia in a patient with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32440985|t=2020. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.|pdf=|usr=008}} | ||
| + | {{tp|p=32424482|t=2020. Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32415314|t=2020. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32447121|t=2020. Unheralded Lower Limb Threatening Ischemia in a COVID-19 Patient.|pdf=|usr=008}} | ||
| + | {{ttp|p=32422349|t=2020. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection.|pdf=|usr=008}} | ||
| + | {{tp|p=32514682|t=2020. Managing anticoagulation in the COVID-19 era between lockdown and reopening phases.|pdf=|usr=008}} | ||
| + | {{tp|p=32504198|t=2020. The burden of thrombotic complications in critically ill patients with COVID-19: charting the uncharted.|pdf=|usr=008}} | ||
| + | {{tp|p=32490908|t=2020. COVID-19 pneumonia: a risk factor for pulmonary thromboembolism?|pdf=|usr=008}} | ||
| + | {{tp|p=32521707|t=2020. Non-Overt Coagulopathy in Non-ICU Patients with Mild to Moderate COVID-19 Pneumonia.|pdf=|usr=008}} | ||
| + | {{tp|p=32479784|t=2020. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32414622|t=2020. Intravenous Thrombolysis for Stroke in a COVID-19 Positive Filipino Patient, a Case Report.|pdf=|usr=008}} | ||
| + | {{tp|p=32402522|t=2020. Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32305883|t=2020. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.|pdf=|usr=008}} | ||
| + | {{tp|p=32362977|t=2020. Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection.|pdf=|usr=008}} | ||
| + | {{tp|p=32504450|t=2020. Dysfunctional Coagulation in COVID-19: From Cell to Bedside.|pdf=|usr=008}} | ||
| + | {{tp|p=32452874|t=2020. Thrombosis and coagulopathy in COVID-19 patients requiring extracorporeal membrane oxygenation.|pdf=|usr=008}} | ||
| + | {{tp|p=32474145|t=2020. COVID-19-Related Aortic Thrombosis: A Report of Four Cases.|pdf=|usr=008}} | ||
| + | {{tp|p=32473304|t=2020. Abdominal Aortic Thrombosis Complicating COVID-19 Pneumonia.|pdf=|usr=008}} | ||
| + | {{tp|p=32473303|t=2020. Inferior vena cava filter in a patient with COVID-19 pneumonia to prevent a massive pulmonary embolism.|pdf=|usr=008}} | ||
| + | {{tp|p=32440663|t=2020. Pulmonary Thromboembolism as a Potential Cause of Clinical Deterioration in COVID-19 Patients; a Commentary.|pdf=|usr=008}} | ||
| + | {{tp|p=32422061|t=2020. Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?|pdf=|usr=008}} | ||
| + | {{tp|p=32422076|t=2020. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series.|pdf=|usr=008}} | ||
| + | {{tp|p=32425319|t=2020. COVID-19 infection with extensive thrombosis: A case of phlegmasia cerulea dolens.|pdf=|usr=008}} | ||
| + | {{tp|p=32492443|t=2020. Right-to-left interatrial shunt in COVID-19 patients with pulmonary embolism.|pdf=|usr=008}} | ||
| + | {{tp|p=32437961|t=2020. Coagulation changes and thromboembolic risk in COVID-19 pregnant patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32437586|t=2020. Understanding the COVID-19 coagulopathy spectrum.|pdf=|usr=008}} | ||
| + | {{tp|p=32426575|t=2020. Clot in Transit on Transesophageal Echocardiography in a Prone Patient with COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=008}} | ||
| + | {{tp|p=32468143|t=2020. Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak.|pdf=|usr=008}} | ||
| + | {{tp|p=32419077|t=2020. Spontaneous Bleedings in COVID-19 Patients: An Emerging Complication.|pdf=|usr=008}} | ||
| + | {{tp|p=32417209|t=2020. Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?|pdf=|usr=008}} | ||
| + | {{tp|p=32516478|t=2020. Severe bleeding in a patient with Factor XIII deficiency and COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32301349|t=2020. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.|pdf=|usr=008}} | ||
| + | {{tp|p=32445671|t=2020. Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?|pdf=|usr=008}} | ||
| + | {{tp|p=32400024|t=2020. More on COVID-19 coagulopathy in Caucasian patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32392353|t=2020. More on: 'COVID-19 coagulopathy in Caucasian patients'.|pdf=|usr=008}} | ||
| + | {{tp|p=32500226|t=2020. Antiphospholipid antibodies in patient with acute lower member ischemia and pulmonary thromboembolism as a result of infection by SARS-CoV2.|pdf=|usr=008}} | ||
| + | {{tp|p=32529774|t=2020. High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a Link with Hypercoagulability?|pdf=|usr=008}} | ||
| + | {{tp|p=32515699|t=2020. [The Agreed Experts' Position of the Eurasian Association of Therapists on Some new Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and Blood gas Exchange].|pdf=|usr=008}} | ||
| + | {{tp|p=32526092|t=2020. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.|pdf=|usr=008}} | ||
| + | {{tp|p=32526058|t=2020. Response to 'all these D-dimers in COVID-19'.|pdf=|usr=008}} | ||
| + | {{tp|p=32531536|t=2020. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?|pdf=|usr=008}} | ||
| + | {{tp|p=32529517|t=2020. Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment.|pdf=|usr=008}} | ||
| + | {{tp|p=31471666|t=2019. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.|pdf=|usr=008}} | ||
| + | {{tp|p=32509485|t=2020. Coronavirus Disease 2019 (COVID-19) Infection Associated With Antiphospholipid Antibodies and Four-Extremity Deep Vein thrombosis in a Previously Healthy Female.|pdf=|usr=008}} | ||
| + | {{tp|p=32487231|t=2020. Severe pulmonary embolism in COVID-19 patients: a call for increased awareness.|pdf=|usr=008}} | ||
| + | {{tp|p=32487122|t=2020. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study.|pdf=|usr=008}} | ||
| + | {{tp|p=32527297|t=2020. Severe Covid-19 disease: rather AVDS than ARDS?|pdf=|usr=008}} | ||
| + | {{tp|p=32527286|t=2020. COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?|pdf=|usr=008}} | ||
| + | {{tp|p=32522226|t=2020. Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!|pdf=|usr=008}} | ||
| + | {{tp|p=32530413|t=2020. Pulmonary Artery Embolism in COVID-19 Despite Thrombosis Prophylaxis.|pdf=|usr=008}} | ||
| + | {{tp|p=32467443|t=2020. Coagulopathy of Coronavirus Disease 2019.|pdf=|usr=008}} | ||
| + | {{tp|p=32396506|t=2020. COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.|pdf=|usr=008}} | ||
| + | {{tp|p=32396627|t=2020. Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation.|pdf=|usr=008}} | ||
| + | {{tp|p=32383737|t=2020. The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32523963|t=2020. Pulmonary embolism: yet another cause of hypoxaemic respiratory failure in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32523928|t=2020. D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients.|pdf=|usr=008}} | ||
| + | {{ttp|p=32489244|t=2020. Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings.|pdf=|usr=008}} | ||
| + | {{tp|p=32523920|t=2020. COVID-19 and Pulmonary Embolism: Not a Coincidence.|pdf=|usr=008}} | ||
| + | {{tp|p=32390931|t=2020. A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis.|pdf=|usr=008}} | ||
| + | {{tp|p=32398297|t=2020. Pulmonary embolism in patients with Covid-19 pneumonia.|pdf=|usr=008}} | ||
| + | {{tp|p=32398294|t=2020. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?|pdf=|usr=008}} | ||
| + | {{tp|p=32399449|t=2020. Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | |||
| + | {{tp|p=32493073|t=2020. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting.|pdf=|usr=008}} | ||
| + | {{tp|p=32515336|t=2020. [Forhojet D-dimer og karakteristiske billeddiagnostiske fund hos patient med COVID-19].|pdf=|usr=008}} | ||
| + | {{tp|p=32515339|t=2020. [Venous thromboembolism in patients with COVID-19].|pdf=|usr=008}} | ||
| + | |||
| + | {{tp|p=32530411|t=2020. Pulmonary Embolism in Covid-19. Coagulation Parameters, Close Monitoring to Prevent?|pdf=|usr=008}} | ||
Aktuelle Version vom 12. September 2020, 17:21 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
D further streaming-in related content is here
Since there are many organ manifestations of Hypercoagulation, subcategorization and transcategorization was applied.
- Venous thrombosis
- Pulmonary embolism
- Cerebral embolism
- Myocardial infarction
- Arterial embolism
- Microembolism
- Hypercoagulation
- Antiphospholipid antibodies
- Disseminated intravascular coagulation
- Bleeding
- Labwork of Thrombembolism
- Prophylaxis of Thrombembolism
The unifying concept behind is Dysendotheliopathies with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.
- papers on various thromboembolic manifestations
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
32360371 ä. Thromboembolic events in patients with SARS-CoV-2
C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
- papers on Hypoxemia
32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
- others
32462990 2020. COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.
32338320 ä. Covid-19 treatment update: follow the scientific evidence
32501145 2020. Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).
32459857 2020. D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue?
32314950 2020. Society for Vascular Medicine (SVM) Leaders Respond to the COVID-19 Crisis.
32447301 2020. Coexistent COVID-19 pneumonia and pulmonary embolism: challenges in identifying dual pathology.
32455440 2020. Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.
32396963 2020. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?
32512587 2020. Bleeding and Bleeding Risk in COVID-19.
32463186 2020. Lungeembolisme ved covid-19.
32425013 2020. COVID-19 and coagulative axis: review of emerging aspects in a novel disease.
32469410 2020. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).
32392741 2020. Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.
32447934 2020. [Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia].
32395964 2020. Do's-and-don'ts bij COVID-19-coagulopathie.
32454268 2020. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.
32507399 2020. Tromboembolismo pulmonar y COVID-19: un cambio de paradigma.
32380898 2020. The "venous perspective" in Lombardia (Italy) during the first weeks of the COVID-19 epidemic.
32490886 2020. Is there a rationale for heparin use among severe COVID-19 patients?
32453702 2020. Procoagulatio, hypercoagulatio es fibrinolysis "shut down" kimutatasa ClotPro(R) viszkoelasztikus tesztek segitsegevel COVID-19-betegekben.
32427809 2020. Inflammatory and Coagulative Considerations for the Management of Orthopaedic Trauma Patients with COVID-19: A Review of the Current Evidence and Our Surgical Experience.
32426897 2020. Heparin - an old drug with multiple potential targets in Covid-19 therapy.
32415902 2020. Ibuprofen and thromboembolism in SARS-COV2.
32506364 2020. Hyperacute multi-organ thromboembolic storm in COVID-19: a case report.
32504449 2020. Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients.
32464707 2020. Macrothrombosis and stroke in patients with mild Covid-19 infection.
32470213 2020. All those D-dimers in COVID-19.
32470207 2020. Frequency of lupus anticoagulant in Covid-19 patients.
32470198 2020. Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.
32470154 2020. Reply to 'Ibuprofen and thromboembolism in SARS-COV2'.
32470156 2020. The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome.
32393875 2020. Coronavirus blood-clot mystery intensifies.
32497287 2020. Anticardiolipin antibodies and COVID-19-A case report from America.
32495985 2020. The association between D-dimers in COVID-19 patients and mortality remains beset of uncertainties.
32409435 2020. Coagulopathy in COVID-19.
32505779 2020. Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?
32512349 2020. Clinically significant anticardiolipin antibodies associated with COVID-19.
32468942 2020. A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19.
32464676 2020. Haemostasis in Times of COVID-19.
32498097 2020. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.
32476551 2020. Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?
32429774 2020. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system.
32508034 2020. Predicted value of coagulation function for prognosis and admission time to negative RT-PCR detection in non-critical COVID-19 patients.
| 32508062 2020. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. |
32432563 2020. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation.
32421381 2020. Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome.
32412320 2020. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan.
32508261 2020. Hypoalbuminemia, Coagulopathy and Vascular Disease in Covid-19.
32463538 2020. Excess out-of-hospital deaths during COVID-19 outbreak: evidence of pulmonary embolism as a main determinant.
32406381 2020. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.
32423903 2020. Thrombotic risk in COVID-19: a case series and case-control study.
32491074 2020. COVID-19 e Estado de Hipercoagulabilidade: Uma Nova Perspectiva Terapeutica.
32396903 2020. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
32500589 2020. Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D - Dimer: COVID 19 and Superficial thrombophlebitis.
| 32459672 2020. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. |
32503799 2020. Abrupt deterioration and pulmonary embolism in COVID-19: a case report.
32452757 2020. Vascular injury and COVID-19-related mortality: What lies below the tip of the iceberg?
32512408 2020. The choice of intravenous thrombolysis for Acute Ischemic Stroke under COVID-19 infection.
32453688 2020. COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.
32438458 2020. Molecular mechanisms for thrombosis risk in Black people: a role in excess mortality from COVID-19.
32425273 2020. Pulmonary embolism and Sars-Cov-2 infection: A new indication for surgical pulmonary endarterectomy?
32420615 2020. Dynamic relationship between D-dimer and COVID-19 severity.
32510975 2020. Thromboprophylaxis in COVID-19: Anti-FXa - The Missing Factor?
32383969 2020. Segmental Pulmonary Vascular Changes in COVID-19 Pneumonia.
32478611 2020. Reply to "Segmental Pulmonary Vascular Changes in COVID-19 Pneumonia".
32506683 2020. D-dimer triage for COVID-19.
32484901 2020. Re The source of elevated plasma D-dimer levels in COVID-19 infection.
32497248 2020. Pulmonary Artery Thrombectomy - A Life Saving Treatment in a Patient with Presumed COVID-19 complicated by a massive Pulmonary Embolus.
32484907 2020. Prevalence of Venous Thromboembolism in Critically Ill Patients with COVID-19.
32420614 2020. First COVID-19 maternal mortality in the UK associated with thrombotic complications.
32439704 2020. Covid-19 and thrombosis: what do we know about the risks and treatment?
32462179 2020. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.
32492712 2020. COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.
32425236 2020. Acute Pulmonary Embolism: An unseen villain in COVID-19.
32532932 2020. Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?
32532939 2020. The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
32532948 2020. Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
32497796 2020. Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.
32471650 2020. Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients.
32435822 2020. Incidence of pulmonary embolism in patients with COVID-19.
32435823 2020. Prothrombotic phenotype in COVID-19 severe patients.
32405288 2020. Acute upper limb ischemia in a patient with COVID-19.
32440985 2020. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.
32424482 2020. Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19.
32415314 2020. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
32447121 2020. Unheralded Lower Limb Threatening Ischemia in a COVID-19 Patient.
| 32422349 2020. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. |
32514682 2020. Managing anticoagulation in the COVID-19 era between lockdown and reopening phases.
32504198 2020. The burden of thrombotic complications in critically ill patients with COVID-19: charting the uncharted.
32490908 2020. COVID-19 pneumonia: a risk factor for pulmonary thromboembolism?
32521707 2020. Non-Overt Coagulopathy in Non-ICU Patients with Mild to Moderate COVID-19 Pneumonia.
32479784 2020. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients.
32414622 2020. Intravenous Thrombolysis for Stroke in a COVID-19 Positive Filipino Patient, a Case Report.
32402522 2020. Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients.
32305883 2020. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.
32362977 2020. Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection.
32504450 2020. Dysfunctional Coagulation in COVID-19: From Cell to Bedside.
32452874 2020. Thrombosis and coagulopathy in COVID-19 patients requiring extracorporeal membrane oxygenation.
32474145 2020. COVID-19-Related Aortic Thrombosis: A Report of Four Cases.
32473304 2020. Abdominal Aortic Thrombosis Complicating COVID-19 Pneumonia.
32473303 2020. Inferior vena cava filter in a patient with COVID-19 pneumonia to prevent a massive pulmonary embolism.
32440663 2020. Pulmonary Thromboembolism as a Potential Cause of Clinical Deterioration in COVID-19 Patients; a Commentary.
32422061 2020. Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?
32422076 2020. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series.
32425319 2020. COVID-19 infection with extensive thrombosis: A case of phlegmasia cerulea dolens.
32492443 2020. Right-to-left interatrial shunt in COVID-19 patients with pulmonary embolism.
32437961 2020. Coagulation changes and thromboembolic risk in COVID-19 pregnant patients.
32437586 2020. Understanding the COVID-19 coagulopathy spectrum.
32426575 2020. Clot in Transit on Transesophageal Echocardiography in a Prone Patient with COVID-19 Acute Respiratory Distress Syndrome.
32468143 2020. Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak.
32419077 2020. Spontaneous Bleedings in COVID-19 Patients: An Emerging Complication.
32417209 2020. Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?
32516478 2020. Severe bleeding in a patient with Factor XIII deficiency and COVID-19.
32301349 2020. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.
32445671 2020. Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?
32400024 2020. More on COVID-19 coagulopathy in Caucasian patients.
32392353 2020. More on: 'COVID-19 coagulopathy in Caucasian patients'.
32500226 2020. Antiphospholipid antibodies in patient with acute lower member ischemia and pulmonary thromboembolism as a result of infection by SARS-CoV2.
32529774 2020. High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a Link with Hypercoagulability?
32515699 2020. [The Agreed Experts' Position of the Eurasian Association of Therapists on Some new Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and Blood gas Exchange].
32526092 2020. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
32526058 2020. Response to 'all these D-dimers in COVID-19'.
32531536 2020. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?
32529517 2020. Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment.
31471666 2019. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
32509485 2020. Coronavirus Disease 2019 (COVID-19) Infection Associated With Antiphospholipid Antibodies and Four-Extremity Deep Vein thrombosis in a Previously Healthy Female.
32487231 2020. Severe pulmonary embolism in COVID-19 patients: a call for increased awareness.
32487122 2020. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study.
32527297 2020. Severe Covid-19 disease: rather AVDS than ARDS?
32527286 2020. COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
32522226 2020. Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!
32530413 2020. Pulmonary Artery Embolism in COVID-19 Despite Thrombosis Prophylaxis.
32467443 2020. Coagulopathy of Coronavirus Disease 2019.
32396506 2020. COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.
32396627 2020. Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation.
32383737 2020. The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.
32523963 2020. Pulmonary embolism: yet another cause of hypoxaemic respiratory failure in COVID-19.
32523928 2020. D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients.
| 32489244 2020. Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings. |
32523920 2020. COVID-19 and Pulmonary Embolism: Not a Coincidence.
32390931 2020. A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis.
32398297 2020. Pulmonary embolism in patients with Covid-19 pneumonia.
32398294 2020. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?
32399449 2020. Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?
32493073 2020. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting.
32515336 2020. [Forhojet D-dimer og karakteristiske billeddiagnostiske fund hos patient med COVID-19].
32515339 2020. [Venous thromboembolism in patients with COVID-19].
32530411 2020. Pulmonary Embolism in Covid-19. Coagulation Parameters, Close Monitoring to Prevent?
